Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Stemline Therapeutics Inc. STML

Healthcare Biotechnology
Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is involved in the business of discovering, acquiring and developing and commercializing therapeutics for oncology indications of unmet medical need. Its pipeline product candidates include felezonexor (SL-801, an XPO1 inhibitor), SL-1001 (a RET kinase inhibitor), SL-901 (a kinase inhibitor) and SL-701 (an... see more

Recent & Breaking News (NDAQ:STML)

Stemline Investor Loss Alert: Hagens Berman Alerts Investors in Stemline Therapeutics to Securities Class Action and Lead Plaintiff Deadline

GlobeNewswire February 6, 2017

SHAREHOLDER COMPLAINT: Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc.

GlobeNewswire February 6, 2017

Why A Patient Death Doesn't Necessarily Scuttle Stemline's Chances For SL-401 Approval

Benzinga.com  February 6, 2017

Johnson & Weaver, LLP Announces Investigations of Stemline Therapeutics, Inc., Psychemedics Corporation and Ultratech, Inc.

PR Newswire February 6, 2017

Shareholder Class Action Lawsuit Filed Against Stemline Therapeutics, Inc - STML

PR Newswire February 4, 2017

A First Take On Stemline's Pivotal BPDCN Study Patient Death

Benzinga.com  February 3, 2017

INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Stemline Therapeutics, Inc. Investors

Business Wire February 3, 2017

IMPORTANT EQUITY ALERT: Lundin Law PC Announces an Investigation of Stemline Therapeutics, Inc. and Advises Investors with Losses to Contact the Firm

Business Wire February 3, 2017

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Stemline Therapeutics, Inc. - STML

Business Wire February 3, 2017

Glancy Prongay & Murray LLP Commences Investigation on Behalf of Stemline Therapeutics, Inc. Investors

Business Wire February 3, 2017

INVESTOR ALERT: Abraham, Fruchter & Twersky LLP Announces Investigation of Securities Claims Against Stemline Therapeutics, Inc. - STML

Business Wire February 3, 2017

Important Information for Stemline Investors: Hagens Berman is Investigating Reported Omission of Patient Death One Day Before Stock Offering

PR Newswire February 3, 2017

STEMLINE (STML) ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Investigates Stemline Therapeutics, Inc.; Encourages Investors to Contact the Firm for Additional Information

PR Newswire February 3, 2017

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Stemline Therapeutics, Inc. and Advises Investors with Losses to Contact the Firm

Business Wire February 3, 2017

Bragar Eagel & Squire, P.C. Is Investigating Stemline Therapeutics, Inc. (STML) on Behalf of Stockholders and Encourages Investors to Contact the Firm

Business Wire February 2, 2017

Stemline Therapeutics Provides Update on Pivotal BPDCN Trial

GlobeNewswire February 2, 2017

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Stemline Therapeutics, Inc. and Encourages Investors to Contact the Firm

Business Wire February 2, 2017

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Stemline Therapeutics, Inc. -- STML

PR Newswire February 2, 2017

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Stemline Therapeutics, Inc. and Advises Investors with Losses to Contact the Firm

Business Wire February 2, 2017

New York Metro Superlawyer, Lynda J. Grant, Investigates Potential Fraud Claims against Stemline Therapeutics, Inc. (“STML: NASDAQ”)

Business Wire February 2, 2017